Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37948336)

  • 1. Dual targeting of Mcl-1 and Bcl-2 to overcome chemoresistance in cervical and colon cancer.
    Wang L; Xi C; Liu R; Ye T; Xiang N; Deng J; Li H
    Anticancer Drugs; 2024 Mar; 35(3):219-226. PubMed ID: 37948336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3- and GSK3β-mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma.
    Maji S; Shriwas O; Samal SK; Priyadarshini M; Rath R; Panda S; Das Majumdar SK; Muduly DK; Dash R
    Carcinogenesis; 2019 Mar; 40(1):173-183. PubMed ID: 30395230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.
    Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2286-2292. PubMed ID: 29959920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual targeting Bcl-2 and Bcl-xL augments osteosarcoma response to doxorubicin.
    Cao C; Pei Y; Yu H; Qi H
    J Chemother; 2024 Apr; 36(2):156-166. PubMed ID: 37309095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.
    Thus YJ; De Rooij MFM; Swier N; Beijersbergen RL; Guikema JEJ; Kersten MJ; Eldering E; Pals ST; Kater AP; Spaargaren M
    Haematologica; 2023 Mar; 108(3):797-810. PubMed ID: 36226498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.
    Daressy F; Séguy L; Favre L; Corvaisier S; Apel C; Groo AC; Litaudon M; Dumontet V; Malzert-Fréon A; Desrat S; Roussi F; Robert A; Wiels J
    Biomed Pharmacother; 2022 Oct; 154():113546. PubMed ID: 35988426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer.
    Zhu Y; Wang C; Li M; Yang X
    J Pharm Pharmacol; 2021 Sep; 73(10):1418-1426. PubMed ID: 34254647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting MCL-1 in hematologic malignancies: Rationale and progress.
    Wei AH; Roberts AW; Spencer A; Rosenberg AS; Siegel D; Walter RB; Caenepeel S; Hughes P; McIver Z; Mezzi K; Morrow PK; Stein A
    Blood Rev; 2020 Nov; 44():100672. PubMed ID: 32204955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib is a dual inhibitor of hepatocellular carcinoma and angiogenesis in an EGFR-independent manner, and synergizes with venetoclax.
    Huang Q; He S; Zhan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10727-10735. PubMed ID: 37310474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
    Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M
    Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.
    Melvold K; Giliberto M; Karlsen L; Ayuda-Durán P; Hanes R; Holien T; Enserink J; Brown JR; Tjønnfjord GE; Taskén K; Skånland SS
    Mol Oncol; 2022 Mar; 16(5):1153-1170. PubMed ID: 34861096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK-75 overcomes venetoclax resistance
    Huang S; Liu Y; Chen Z; Wang M; Jiang VC
    Am J Cancer Res; 2022; 12(3):1102-1115. PubMed ID: 35411248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
    Thus YJ; Eldering E; Kater AP; Spaargaren M
    Leukemia; 2022 Sep; 36(9):2165-2176. PubMed ID: 35725771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.
    Xu M; Tao Z; Wang S; Jiang Y; Qu M
    Biochem Biophys Res Commun; 2019 May; 512(4):902-907. PubMed ID: 30929914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting MCL-1 protein to treat cancer: opportunities and challenges.
    Tantawy SI; Timofeeva N; Sarkar A; Gandhi V
    Front Oncol; 2023; 13():1226289. PubMed ID: 37601693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
    Singh Mali R; Zhang Q; DeFilippis RA; Cavazos A; Kuruvilla VM; Raman J; Mody V; Choo EF; Dail M; Shah NP; Konopleva M; Sampath D; Lasater EA
    Haematologica; 2021 Apr; 106(4):1034-1046. PubMed ID: 32414851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
    Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
    Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.